NCT01093040View on ClinicalTrials.gov

A Study to Assess the Safety and Immunogenicity of the Drug CAT-354 in Healthy Japanese Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

May 31, 2010

Study Completion Date

October 31, 2010

Conditions

Healthy

Interventions

DRUG

CAT-354

150 mg CAT-354 or placebo given SC on Day 1

DRUG

CAT-354

300 mg CAT-354 or placebo given SC on Day 1

DRUG

CAT 354

600 mg CAT-354 or placebo given SC on Day 1

Trial Locations (1)

91206

Research Site, Glendale

Sponsors

Lead Sponsor

Collaborators (2)

All Listed Sponsors

collaborator

MedImmune Ltd

INDUSTRY

collaborator

AstraZeneca

INDUSTRY

lead

MedImmune LLC

INDUSTRY